It is not the same everywhere. There are many companies that are exciting to work for, have an enthusiasm for their customers, and their business, and developing new technologies. They're on the cutting edge. Safety devices are not cutting edge. Look at companies like Molecular Device, PE Biosystems, Agilent, even the dreaded Beckman Coulter. Look at what they bring to market, talk to their sales people. BD used to be like these companies, the "One Company" approach has not worked in the past with other comapnies, is not working now, and will probably be tinkered with again before all is said an done. Market specialization, and diversification in the biotech marketplace is essential for BD survival. The fact that BDB is a business in excess of $1 billion dollars should offer some clue. BD used to be the great company that Cleteo dreamed it should be, it wasn't long ago the stock was $80! Oh, and in my opinion, my analysis of the business is correct, $27 a share yesterday, get real!